Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data

World Journal of Urology 2026

View at publisher

Authors: Jingwen Lin, Wu Fu, Jiaying Huang, M. Liu, Hongfu Cai

DOI: 10.1007/s00345-026-06237-z

Cited by: 2

References: 1

Fields of Study & Subjects

Psoriasis: Treatment and Pathogenesis Cancer Immunotherapy and Biomarkers Autoimmune Bullous Skin Diseases

References 1